204 related articles for article (PubMed ID: 36708462)
1. Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.
Yang D; Tan J; Long Y; Huang K; Han W; Wang M; Zhu S; Zeng S; Yi W
Aging Clin Exp Res; 2023 Mar; 35(3):531-539. PubMed ID: 36708462
[TBL] [Abstract][Full Text] [Related]
2. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
3. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Hagino H; Tanaka S; Kuroda T; Mori S; Soen S
J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
[TBL] [Abstract][Full Text] [Related]
5. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
7. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.
Tseng YY; Su CH; Lui TN; Yeh YS; Yeh SH
Osteoporos Int; 2012 May; 23(5):1613-22. PubMed ID: 21769661
[TBL] [Abstract][Full Text] [Related]
9. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
10. Effects of teriparatide versus percutaneous vertebroplasty on pain relief, quality of life and cost-effectiveness in postmenopausal females with acute osteoporotic vertebral compression fracture: A prospective cohort study.
Ma Y; Wu X; Xiao X; Ma Y; Feng L; Yan W; Chen J; Yang D
Bone; 2020 Feb; 131():115154. PubMed ID: 31733423
[TBL] [Abstract][Full Text] [Related]
11. [Very old patients with osteoporosis should be treated with alendronate].
Shiraki M
Nihon Ronen Igakkai Zasshi; 2006 Jul; 43(4):455-8. PubMed ID: 16937932
[TBL] [Abstract][Full Text] [Related]
12. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.
Hiligsmann M; Silverman SS; Singer AJ; Pearman L; Mathew J; Wang Y; Caminis J; Reginster JY
Pharmacoeconomics; 2023 Jul; 41(7):819-830. PubMed ID: 37086385
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Le QA; Hay JW; Becker R; Wang Y
Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
[TBL] [Abstract][Full Text] [Related]
16. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
18. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
Wermers RA; Recknor CP; Cosman F; Xie L; Glass EV; Krege JH
Osteoporos Int; 2008 Jul; 19(7):1055-65. PubMed ID: 18283386
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
Mori S; Hagino H; Sugimoto T; Tanaka S; Mitomo Y; Takahashi K; Sone T; Nakamura T; Soen S
Osteoporos Int; 2023 Jan; 34(1):189-199. PubMed ID: 36239756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
